ArticleJournal of pediatric gastroenterology and nutrition2025
Serum adropin is unaltered in adolescents with histology-confirmed steatotic liver disease.
Article in Journal of pediatric gastroenterology and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A comparison of plasma Tsukushi in adolescents with and without metabolic dysfunction-associated steatotic liver disease.Physiological reports · 2026Article
- Endotoxin Markers Are Elevated in Adolescents With Obesity With and Without Metabolic Dysfunction-Associated Steatotic Liver Disease.Pediatric obesity · 2026Article
- Low Levels of Adropin Predicted New Incidents of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesMetabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents is increasing. Adropin is a liver-derived peptide involved in glucose and lipid homeostasis that was shown to be reduced in adults with metabolic disorders and cardiovascular disease (CVD). Serum adropin may also be higher in young men than women. A prior study reported that serum adropin was reduced in adolescents with MASLD, but the relationship between liver histology and CVD risk factors was not reported. We tested the hypotheses that adropin is (1) reduced in adolescents with MASLD compared to adolescents with obesity (Ob) or normal weight (NW) without MASLD, (2) correlated with blood pressure (BP), arterial stiffness, and liver histopathology, and (3) higher in boys than girls.
methodsSerum adropin was measured in 47 patients with MASLD, and 27 and 29 control participants with Ob or NW, respectively.
resultsAdropin was not reduced but was instead 5% and 20% higher (p > 0.42) in the MASLD compared to the Ob and NW groups, respectively. Adropin concentration was not correlated with arterial stiffness or BP. Adropin was 20% higher in boys than girls in the entire study cohort (p = 0.034). This difference was evident in the Ob group (p = 0.018), but not in the NW (p = 0.537) or the MASLD (p = 0.893) groups. Adropin was positively correlated with age within the MASLD group only (r = 0.46, p < 0.001).
conclusionSerum adropin was not reduced in adolescents with Ob or MASLD as reported previously. The positive relationship between age and adropin in adolescents with MASLD requires further examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.